Panel to Review Gadolinium Retention in Contrast Agents
Federal Register notice: FDA has announced a 9/8 Medical Imaging Drugs Advisory Committee meeting. Panel members will discuss the potential risk of gadolinium retention in the brain and other body organs in patients receiving gadolinium-based contrast agents for magnetic resonance clinical imaging procedures. To view the notice, click here.